Plasma biomarkers of Alzheimers pathology have been studied in relation to cognitive decline and dementia, but no prior study has examined their associations with longevity or healthspan. In this cohort study of older women (N=2,576), we examined plasma biomarkers measured at baseline when women were cognitively unimpaired. We found that plasma biomarkers were associated with both exceptional longevity and healthspan, defined as survival to age 90 without cognitive impairment. Elevated levels of plasma p-tau217 (OR, 0.58; 95% CI, 0.50-0.68), p-tau181 (OR, 0.81; 95% CI, 0.71 - 0.93), NfL (OR, 0.70; 95% CI, 0.60 - 0.82) and GFAP (OR, 0.78; 95% CI, 0.68 - 0.90) were all associated with reduced odds of healthspan; findings survived adjustment for multiple comparisons. These findings suggest that plasma biomarkers may not only reflect ADRD pathology but also systemic aging processes that underlie lifespan and healthspan, underscoring their potential value as novel biomarkers of aging.
Associations of plasma biomarkers of Alzheimer's pathology with longevity and healthspan
TL;DR
Plasma biomarkers of Alzheimers pathology have been studied in relation to cognitive decline and dementia, but no prior study has examined their associations with longevity or healthspan. In this cohort study of older women (N=2,576), we examined plasma biomarkers measured at baseline when women were cognitively unimpaired. We found that plasma biomarkers were associated with both exceptional longevity and healthspan, defined as survival to age 90 without cognitive impairment. Elevated levels of
Credibility Assessment
Preliminary — 34/100
Study Design
Rigor of the research methodology
5/20
Sample Size
Whether the study was sufficiently powered
7/20
Peer Review
Review status and journal reputation
4/20
Replication
Has this finding been independently reproduced?
6/20
Transparency
Funding disclosure and data availability
12/20
Overall
Sum of all five dimensions
34/100
0 Comments
Log in to join the discussion.